Talking Medicines identified as top AI Company
November 16, 2020

Data tech innovator Talking Medicines, which uses advanced AI to provide pharmaceutical companies with real-time data intelligence, has been chosen to join Tech Nation’s Applied AI 2.0 Growth Programme. Tech Nation’s growth programmes are designed to champion and support ‘the UK’s most exceptional deep tech scaleups’ and alumni include Skyscanner, Darktrace, and Monzo. The programme forms part of the UK Government’s AI Sector Deal, supported by the Office for AI.

Glasgow and London-based Talking Medicines was selected to join the programme after a competitive and rigorous judging process. The programme supports companies, according to Tech Nation, to ‘scale up and become the AI unicorns of the future’.

Formed in 2013 to create new ways of capturing the digital voice of the patient, Talking Medicines uses a collection of tech tools to capture and analyse the conversations and behaviours of patients at home.Through mapping the patient voice to regulated medicine information, the company is able to build data points to deliver trends and patterns of usage across medicines and brands driven by the health consumer. This intelligence enables marketing in big pharma to score patient confidence in their medicines. Real-time, compliant insights can replace traditional focus groups, prescriber reports and clinical profiles to tell pharmaceutical companies who is using their medicines, how, and what they really think of their brands.

Dr Elizabeth Fairley, COO, Talking Medicines, said: “Our aim is to help people take the right medicines that have the best chance of working for them. Pharmaceutical companies are becoming more aware of the need to measure the performance of drugs and identify strategies for improvement post launch. Our systems use AI to cleanse and structure information from millions of conversations and direct patient-use data.

“Being selected for the Tech Nation’s Applied AI 2.0 Growth Programme has happened at just the right time for us to take our scalable data intelligence product to the next level. Through this programme we are keen to push our boundaries, connect with the very best in AI and learn as much as we can.”

Recent Blogs

COVID-19 Vaccine: A fresh start

COVID-19 Vaccine: A fresh start

There is no doubt that 2020 has been a long, hard year. With the endless threat of new measures and long lockdowns, it is safe to say we could do with some good news. Finally, we have a glimmer of hope. First, Pfizer (Pharmaceutical company) announced the interim...

Talking Medicines builds a world class team

Talking Medicines builds a world class team

Hot off of the press on raising £1.1M Talking Medicines are building out a world class product and tech team to realise its mission of creating the world’s first social intelligence company for the pharmaceutical industry.  In line with plans to scale up its AI-based...

Talking Medicines secures new funds from Tern PLC

Talking Medicines secures new funds from Tern PLC

Talking Medicines, the world’s first social intelligence company for the pharmaceutical industry, has received a significant boost with a £1.1 million funding deal to scale up its AI-based data technology platform for measuring patient sentiment. Tern Plc, the...

MedTech Integrates – The importance of listening to patient need

MedTech Integrates – The importance of listening to patient need

A couple of weeks ago our COO, Dr Elizabeth Fairley took part in a panel discussion about the feasibility of MedTech in the developing world and whether it can be a sustainable model.2 We represent a different proposition to the other panellists, their experience is...